Felicetto Ferrara

In their paper, Delia et al.1 report a retrospective analysis of 78 patients with acute myeloid leukaemia (AML) deemed unfit for intensive chemotherapy according to the Ferrara criteria2 and treated with either single-agent hypomethylating agents (HMAs) or in combination with venetoclax (VEN).

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 27 September 2024 / Approved: 29 September 2024 / Online: 30 September 2024 (09:19:50 CEST) Molica, M.; Canichella, M.; Jabbour, E.; Ferrara, F. Evaluating Fitness in Older Acute Myeloid Leukemia Patients: Balancing Therapy and Treatment Risks. Preprints 2024, 2024092322. https://doi.org/10.20944/preprints202409.2322.v1 Molica, M.; Canichella, M.; Jabbour, E.; Ferrara, F.